A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
about
Signaling Pathways in Thyroid Cancer and Their Therapeutic ImplicationsPazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.Novel therapies for thyroid cancer.Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Management of hereditary medullary thyroid carcinoma.Evolving molecularly targeted therapies for advanced-stage thyroid cancers.The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies.Targeted Therapies in Thyroid Cancer: An Extensive Review of the Literature.Medullary Thyroid Carcinoma: Recent Advances Including MicroRNA Expression.Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.Advances in small molecule therapy for treating metastatic thyroid cancer.Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines.Targeted Therapy for Medullary Thyroid Cancer: A Review.Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study.
P2860
Q26764899-3F04C361-B54B-4DFD-AD9A-E11919DD1931Q36482433-39DE1922-C08F-479F-964B-5A7D52EF7DE6Q38260495-0D01A30E-781F-4905-BFCC-1E213CE94714Q38543837-8B8DB627-2D52-412A-92C6-580D16D67990Q38625034-52AC468F-72C8-49A7-9412-E5F0F569CF5FQ38683133-F5484BBD-D4E0-481F-86B5-26C2734893CDQ38721033-9E780809-74F2-43B8-9C5C-E9EC6342A894Q38754489-F14C7F20-C7EB-4759-9D1D-0947B1EB5575Q38865611-50586A08-0360-4145-AD17-BC4B562C1332Q38883187-5FDA80D5-E1F5-49C1-810D-50DF6866EF7AQ38931460-6F049D1E-4AB1-4C03-94C4-08E8AE04EB2DQ38936104-22EB4890-C518-47E6-9A0D-61459BE699E7Q39364787-BBA16EDD-6FCB-4F29-BAEF-54A9E2ED2FD7Q43424854-E041B6F0-4704-49C7-A233-3915E7A312E6Q46274363-5E071993-680C-46F5-8398-3BABBC496F36Q49328959-DB9918F4-CC7E-474A-856B-5151ABB6FA10Q53658745-83D4760F-1611-4289-8363-4F4CC5034BA6Q55064836-C13161EF-C412-4EE6-A749-512107F701B9
P2860
A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@ast
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@en
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@nl
type
label
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@ast
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@en
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@nl
prefLabel
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@ast
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@en
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@nl
P2093
P2860
P356
P1476
A multicenter phase 2 trial of ...... ary thyroid carcinoma: MC057H.
@en
P2093
Anne M Traynor
Boon Cher Goh
Bryan McIver
Carolyn Bieber
Charles Erlichman
Crescent R Isham
Endocrine Malignancies Disease ...... nd the Mayo Phase 2 Consortium
Jill K Burton
John C Morris
P2860
P304
P356
10.1210/JC.2013-3713
P407
P577
2014-02-25T00:00:00Z